Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Catalyst Biosciences stock

Learn how to easily invest in Catalyst Biosciences stock.

Catalyst Biosciences Inc is a biotechnology business based in the US. Catalyst Biosciences shares (CBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Catalyst Biosciences employs 56 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Catalyst Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CBIO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Catalyst Biosciences stock price (NASDAQ: CBIO)

Use our graph to track the performance of CBIO stocks over time.

Catalyst Biosciences shares at a glance

Information last updated 2022-01-25.
Latest market close$0.59
52-week range$0.58 - $7.55
50-day moving average $1.14
200-day moving average $3.50
Wall St. target price$11.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.06

Buy Catalyst Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Catalyst Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Catalyst Biosciences price performance over time

Historical closes compared with the close of $0.5856 from 2022-01-25

1 week (2022-01-15) N/A
1 month (2021-12-22) N/A
3 months (2021-10-25) -82.88%
6 months (2021-07-26) -86.16%
1 year (2021-01-26) -90.75%
2 years (2020-01-24) -91.29%
3 years (2019-01-25) 7.67
5 years (2017-01-26) 2.74%

Is Catalyst Biosciences stock undervalued or overvalued?

Valuing Catalyst Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalyst Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Catalyst Biosciences's PEG ratio

Catalyst Biosciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.02. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Catalyst Biosciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Catalyst Biosciences financials

Revenue TTM $6.9 million
Gross profit TTM $-40,390,000
Return on assets TTM -56.76%
Return on equity TTM -111.78%
Profit margin 0%
Book value $1.94
Market capitalisation $19.8 million

TTM: trailing 12 months

Catalyst Biosciences share dividends

We're not expecting Catalyst Biosciences to pay a dividend over the next 12 months.

Have Catalyst Biosciences's shares ever split?

Catalyst Biosciences's shares were split on a 1:15 basis on 12 February 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Catalyst Biosciences shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Catalyst Biosciences shares which in turn could have impacted Catalyst Biosciences's share price.

Catalyst Biosciences share price volatility

Over the last 12 months, Catalyst Biosciences's shares have ranged in value from as little as $0.58 up to $7.55. A popular way to gauge a stock's volatility is its "beta".

CBIO.US volatility(beta: 1.82)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Biosciences's is 1.8231. This would suggest that Catalyst Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Catalyst Biosciences overview

Catalyst Biosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company engineer proteases to develop improved or novel molecules to treat diseases that result from dysregulation of the complement and coagulation cascades. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously administered engineered coagulation; and Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. The company's pipeline also includes a preclinical program partnered with Biogen International GmbH for dry age-related macular degeneration (AMD); factor I protease for SQ prophylaxis in patients with complement factor I deficiency and C4b-degraders designed to target disorders of the classical complement pathway, as well as other complement programs. The company also develops CB 4332 intended for lifelong prophylactic SQ administration in individuals with CFI deficiency; and CB 2782-PEG, a C3 degrader product candidate in preclinical development for the treatment of dry AMD. It has a strategic research collaboration with Mosaic Biosciences, Inc.

Frequently asked questions

What percentage of Catalyst Biosciences is owned by insiders or institutions?
Currently 5.744% of Catalyst Biosciences shares are held by insiders and 60.93% by institutions.
How many people work for Catalyst Biosciences?
Latest data suggests 56 work at Catalyst Biosciences.
When does the fiscal year end for Catalyst Biosciences?
Catalyst Biosciences's fiscal year ends in December.
Where is Catalyst Biosciences based?
Catalyst Biosciences's address is: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080
What is Catalyst Biosciences's ISIN number?
Catalyst Biosciences's international securities identification number is: US14888D2080
What is Catalyst Biosciences's CUSIP number?
Catalyst Biosciences's Committee on Uniform Securities Identification Procedures number is: 14888D109

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site